Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will host a webcast on September 7, 2022 at 8:00 AM ET to announce two new indications for batoclimab.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will host a webcast on September 7, 2022 at 8:00 AM ET to announce two new indications for batoclimab. The event will feature remarks from company management and external key opinion leaders, followed by a live Q&A session. Interested participants can register for the webcast here. An archived recording will be available on the company's website afterward.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +4.62%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.
The event will feature prepared remarks by company management and external key opinion leaders. A live question-and-answer session with company management will follow the formal presentations. To access the webcast, please register here.
An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.